is semaglutide the same as tripeptide Why You Might Tolerate One Weight Loss Drug Better Than Another Comparing Semaglutide, Tirzepatide, and Retatrutide

doi:10.1152/ajprenal.00729.2010 217

Landmark Results The Phase 2 results, presented at the American Diabetes Association (ADA) Scientific Sessions in June 2023 and simultaneously published in the New England Journal of Medicine and The Lancet, were transformative: Weight loss : Up to 24.2% mean weight reduction at 48 weeks in the obesity trial (12 mg group), the highest ever reported for a pharmaceutical agent Glycemic control : Up to 2.02% HbA1c reduction in the diabetes trial, with most participants at higher doses achieving non-diabetic HbA1c levels Liver fat : Up to ~82% relative reduction in liver fat content Tolerability : GI adverse event profile consistent with the incretin class

Accessed June 29, 2007

Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, et al